Literature DB >> 29847319

68Ga-PSMA PET/MR-Positive, Histopathology-Proven Prostate Cancer in a Patient With Negative Multiparametric Prostate MRI.

Urs J Muehlematter1, Niels J Rupp2, Julian Mueller3, Daniel Eberli4, Irene A Burger3.   

Abstract

Multiparametric MRI incorporating T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced sequences is currently used for detection and localization of clinically important prostate cancer (PCa). The Ga-labeled PET tracer targeting the prostate-specific membrane antigen (PSMA, Ga-PSMA-11) is a promising diagnostic approach for staging and restating PCa. Recent studies suggest that Ga-PSMA could also be used for primary PCa detection and localization. We report a case of a Ga-PSMA PET/MR-positive lesion of the peripheral zone in a 73-year-old man with a negative preceding multiparametric MRI. Radical prostatectomy and subsequent histopathologic examination confirmed a Gleason 4 + 4 PCa.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29847319     DOI: 10.1097/RLU.0000000000002143

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.

Authors:  Liran Domachevsky; Hanna Bernstine; Natalia Goldberg; Meital Nidam; Onofrio A Catalano; David Groshar
Journal:  Eur Radiol       Date:  2019-07-22       Impact factor: 5.315

2.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

3.  Discrepancy between Multiparametric Magnetic Resonance Imaging and 68Ga Prostate-Specific Membrane Antigen Positron Emission Tomography: A Simultaneous Acquired Positron Emission Tomography-Magnetic Resonance Imaging Case.

Authors:  Naveen Jose Moolan; Vijay Harish Somasundaram; Bindu Mangalath Rajamma; Palaniswamy Shanmugha Sundaram
Journal:  Indian J Nucl Med       Date:  2021-03-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.